Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Articles

August 16, 2023

UNITED STATES: Federal Circuit Agrees with PTAB on Anticipation and Obviousness of GM’s Design Patents

International Trademark Association (INTA)

Firm News

August 11, 2023

Six Sterne Kessler Directors Ranked in Who’s Who Legal: IP 2023 Global Guide

Sterne, Kessler, Goldstein & Fox

Firm News

August 9, 2023

Sterne Kessler Raises Record-Breaking $45,000 for the Legal Aid Society of the District of Columbia

Sterne, Kessler, Goldstein & Fox